COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

被引：0

作者：

Yosuke, Tanaka ^{[1
]}

Mitsunori, Hino ^{[1
]}

Naomi, Onda ^{[1
]}

Hiroyuki, Takoi ^{[1
]}

Seiji, Kosaihira ^{[1
]}

Norihisa, Motohashi ^{[1
]}

Akihiko, Gemma ^{[1
]}

机构：

[1] Chiba Hokusoh Hosp, Resp Dis Ctr, Nippon Med Sch, Chiba, Japan

来源：

RESPIROLOGY | 2014年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

P-F-073

引用

页码：122 / 122

页数：1

共 50 条

[31] Lifetime Benefits for Budesonide/Glycopyrrolate/Formoterol Fumarate versus Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist and Inhaled Corticosteroid/Long-Acting β2-Agonist Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease
De Nigris, E.
Treharne, C.
Brighton, N.
Holmgren, U.
Walker, A.
Haughney, J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
[32] Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Melissa H. Roberts
Douglas W. Mapel
Hans Petersen
Drugs - Real World Outcomes, 2020, 7 : 1 - 17
[33] Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Roberts, Melissa H.
Mapel, Douglas W.
Petersen, Hans
DRUGS-REAL WORLD OUTCOMES, 2020, 7 (01) : 1 - 17
[34] Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis
Oba, Yuji
Sarva, Siva T.
Dias, Sofia
THORAX, 2016, 71 (01) : 15 - 25
[35] Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Welsh, Emma J.
Cates, Christopher J.
Poole, Phillippa
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
[36] Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Joos, Guy F.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (02) : 257 - 264
[37] Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Busch-Petersen, Jakob
Laine, Dramane I.
FUTURE MEDICINAL CHEMISTRY, 2011, 3 (13) : 1623 - 1634
[38] Optimal Bronchodilation for COPD Patients: Are All Long-Acting beta(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
Miravitlles, Marc
Baek, Seungjae
Vithlani, Vatsal
Lad, Rahul
TUBERCULOSIS AND RESPIRATORY DISEASES, 2018, 81 (03) : 198 - 215
[39] Once daily long-acting beta 2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Ibrahim, Abdullahi S.
INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2021, 27 (06)
[40] Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Maqsood, Usman
Ho, Terence N.
Palmer, Karen
Eccles, Fiona J. R.
Munavvar, Mohammed
Wang, Ran
Crossingham, Iain
Evans, David J. W.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (03):

← 1 2 3 4 5 →